A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia

Conditions

• Patients With Chemotherapy-Induced Thrombocytopenia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Hetrombopag Olamine — DRUG
  For Part A, all participants would receive hetrombopag treatment.
• Hetrombopag Olamine ；Hetrombopag Olamine Placebo — DRUG
  For Part B，participants would be randomized to receive hetrombopag treatment or matching placebo, respectively。

Study Details

The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.

Key Dates

Start date

Apr 16, 2026

Status verified

Dec 2025

Primary completion

Dec 31, 2028

Completion

Jun 30, 2029

Study Design

Enrollment

150 participants (estimated)

Allocation

NON_RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

TREATMENT

Arms

• Experimental: Part A: Hetrombopag Olamine
• Experimental: Part B：Hetrombopag Olamine vs Hetrombopag Olamine Placebo

Primary Outcome Measure

Part A: Cmax of hetrombopag in non-Asian participants with CIT, around 6 months. [ Time Frame: around 6 months. ]

Central Contacts

• Junye Xiong
  0518-82342973
  [email protected]

Locations (7)

Find similar trials in Los Alamitos, CA